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Abstract (246 words)  22 
Context: The role of alcohol intake in influencing longitudinal trajectories of adiponectin is unclear. 23 
Objective: To examine the association between alcohol intake and changes in circulating levels of 24 
adiponectin over repeat measures. 25 
Design, setting and participants : A prospective cohort study of 2855 men and women (74% men 26 
with a mean age of 50 years at baseline) drawn from the Whitehall II study. Data from study phases 3 27 
(1991-1993), 5 (1997-1999) and 7 (2002-2004) were used. 28 
Main outcome measure: Adiponectin serum concentrations (ng/mL) were measured and alcohol 29 
intake was defined in terms of number of UK units (1 unit = 8g ethanol) consumed in the previous 7 30 
days on three occasions. Cross-sectional associations between alcohol and adiponectin levels were 31 
calculated using linear regression. A bivariate dual change score model was used to estimate the effect 32 
of alcohol intake on upcoming change in adiponectin. Models were adjusted for age, sex, ethnicity 33 
and smoking status. 34 
Results: Alcohol consumption was cross-sectionally associated with (log-transformed) adiponectin 35 
levels (β ranging from 0.001 to 0.004 depending on phase and level of adjustment), but was not 36 
associated with changes in adiponectin levels over time (γ = -0.002 [SE 0.002], p = 0.246). 37 
Conclusion: Alcohol intake is not associated with changes in circulating adiponectin levels in this 38 
cohort. This finding provides evidence that adiponectin levels are unlikely to mediate the relationship 39 
between moderate alcohol consumption and reduced risk of type 2 diabetes. It is important to consider 40 
dynamic longitudinal relationships rather than cross-sectional associations. 41 
42 
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Introduction 43 
Moderate alcohol intake is associated with a lower risk of developing type 2 diabetes (1) and part of 44 
this effect is thought to be mediated via its role in increasing adiponectin levels (2–6). Higher levels 45 
of circulating adiponectin are alleged to be associated with a lower risk of type 2 diabetes (7) and 46 
prediabetes (8), in addition to cardiovascular disease (9), various forms of cancer (10)  and major 47 
depression (11).  48 
However, the majority of studies linking alcohol intake to adiponectin rely on only one measure of 49 
alcohol consumption at baseline and adiponectin level ascertained either cross-sectionally or at a 50 
single follow-up occasion. It is important to consider the longitudinal development of both processes 51 
to determine how, if at all, the two are related. However, studies with repeat measures of alcohol 52 
consumption and adiponectin are scarce, so few studies have been able to examine the relationship 53 
simultaneously. One study found that changes in drinking over a four year period, specifically the 54 
uptake of modest drinking amongst initial non-drinkers and small increases in consumption amongst 55 
light drinkers, were associated with higher adiponectin levels (12). However, this study was reliant on 56 
a single measure of adiponectin at follow-up amongst only 697 men. Neither alcohol intake nor 57 
circulating levels of adiponectin are static processes (13,14). That is, both change over time and it is 58 
possible that accounting for the dynamic association between the two will shed additional light on the 59 
role of alcohol intake in regulating adiponectin concentrations. The purpose of this study was 60 
therefore to investigate how prospectively measured alcohol consumption is related to changes in 61 
adiponectin levels over repeat measures.  62 
Materials and Methods 63 
Study design and sample 64 
Participants were drawn from the Whitehall II prospective cohort study (15). The study began in 65 
1985-1988 (phase 1) and included 10,308 (6,895 men) British civil servants aged 35-55 years. We 66 
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present data at phases 3 (1991-1993), 5 (1997-1999) and 7 (2002-2004) from a diabetes case-cohort 67 
sample (16,14) with measurements of adiponectin (N=3477 with at least one valid measure). We 68 
excluded those with prevalent diabetes at baseline (N=17). Furthermore we limited our sample to 69 
those who consumed alcohol at some point during follow-up to limit biases associated with lifelong 70 
non-drinking and sick-quitting prior to baseline influencing our estimates (exclusion of N=110) 71 
(17,18). Those with missing data on covariates were also excluded from the analytic sample (N=530), 72 
resulting in a final sample size of 2,855 individuals (note missing data counts for categories above are 73 
not mutually exclusive). Participants excluded from the analytic sample tended to be older, from 74 
lower socioeconomic groups and of non-white ethnicity (there was no gender difference in 75 
participation; data not presented). 76 
The study was approved by the University College London Medical School Committee on the Ethics 77 
of Human Research. Informed consent was obtained at baseline and renewed at each contact. 78 
Whitehall II data, protocols, and other metadata are available to bona fide researchers for research 79 
purposes. Please refer to the Whitehall II data sharing policy at http://www.ucl.ac.uk/whitehallII/data-80 
sharing. 81 
Measurements 82 
Alcohol intake 83 
Participants were asked to report the number of alcoholic drinks they had consumed in the previous 84 
week, providing information separately for beer/cider (pints), wine (glasses), and spirits (measures). 85 
Drinks were converted into UK units of alcohol (one unit is equivalent to 8 g of ethanol) using a 86 
conservative estimate of one UK unit for each measure of spirits and glass of wine, and two UK units 87 
for each pint of beer. The sum of these converted measurements was used to define total weekly 88 
number of UK units consumed. 89 
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Adiponectin 90 
Adiponectin serum concentrations were measured using the Quantikine ELISA kit (R&D Systems, 91 
Wiesbaden, Germany). The same standard operating procedures were followed for blood collection, 92 
processing and storage during all study phases. Venous fasting (≥5 hour of fasting) blood samples 93 
were drawn before a standard 2 hour oral-glucose tolerance test. Within an hour samples were 94 
centrifuged on-site and serum immediately removed from the monovette tubes into microtubes stored 95 
at −80°C. All assays were performed in the same laboratory (German Diabetes Center) and to 96 
minimize imprecision samples from different study phases of the same participant were measured 97 
using the same ELISA plate. The limit of detection was 3.9 ng/mL (all samples gave values above the 98 
limit of detection). 99 
Other covariates 100 
We regressed the intercept and slope terms for both alcohol intake and adiponectin on the following 101 
time-invariant covariates: age at baseline (centered on the sample mean), sex, ethnicity (white vs. non-102 
white) and socioeconomic position defined using employment grade (high, intermediate or low). We 103 
entered smoking status (not current vs. current) as a time-varying covariate influencing adiponectin 104 
levels at each time point (19). We chose not to adjust for variables that may lie on the causal pathway 105 
between alcohol intake and adiponectin levels to avoid overadjustment bias (20,21), this includes 106 
body mass index (22) and fasting insulin (23). Due to our sample size and the complexity of our 107 
longitudinal model we did not stratify by sex or ethnicity. 108 
Statistical analysis 109 
The association between adiponectin and alcohol intake cross-sectionally at each study phase was 110 
calculated using linear regression. To examine the association between adiponectin concentrations 111 
and weekly alcohol intake over repeat measures we used bivariate dual change score (BDCS) 112 
modelling, which allows for growth/decline to be measured whilst simultaneously allowing for lagged 113 
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effects from one process on the upcoming change in the other variable. A detailed explanation of the 114 
mathematical and statistical properties of BDCS models can be found elsewhere (24,25).  115 
Briefly, change in a variable (∆) is considered as a function of three components: (1) a constant 116 
amount (α) which is the sum of change scores over time, (2) an amount proportional to the previous 117 
value of itself (β) – in many ways representing self-feedback in the dynamic system, and (3) an 118 
amount proportional to the previous state of the alternative variable (γ).  It is also important to note 119 
that while BDCS models are usually specified as linear models (i.e. the association between 120 
alcohol intake and changes in adiponectin is linear), nonlinear trajectories can be 121 
accommodated/modelled because at each time point the autoproportional (β) and coupling (γ) 122 
parameters are multiplied by scores from the previous measurement occasion which alter over 123 
time.  The result is that even in a model where the coefficients are assumed to be static over time 124 
the actual effects are compounded across occasions as a result of being multiplied by shifting 125 
values (25,26). 126 
Both the intercepts (estimated values for log-transformed adiponectin and weekly alcohol intake at the 127 
first study phase) and slopes (α terms) were fitted as random effects. Intercepts and slopes were 128 
correlated within single processes (for example, the adiponectin intercept with the adiponectin slope) 129 
and between processes (for example, the alcohol intercept with the adiponectin slope). See Figure 1 130 
for a simplified graphical depiction of the model. As described above, intercepts and slopes were 131 
estimated conditional on baseline covariates whilst smoking status was entered into the model as a 132 
time-varying covariate. As adiponectin values (ng/mL) were heavily positively skewed we used 133 
natural log-transformed values for analysis.  134 
Models were estimated in Mplus version 7.3 (27) using Full Information Maximum Likelihood 135 
(FIML) with Robust Standard Errors. Model fit was examined using the Tucker–Lewis index (TLI), 136 
the comparative fit index (CFI), and the root mean squared error of approximation (RMSEA). Cut-off 137 
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values approaching 0.95 were used to determine a good fit for TLI and CFI, while a threshold close to 138 
0.06 was used for RMSEA (28). Statistical significance was inferred at a two-tailed P < 0.05. 139 
Results 140 
Descriptive statistics 141 
Presented in Table 1 are the basic demographic statistics of the analytic sample. The mean age of 142 
participants at baseline was approximately 50 years (range 40 to 63 years). Almost three quarters of 143 
the sample were men and the majority of them white (approximately 93%) and of high to intermediate 144 
socioeconomic position. Descriptive statistics concerning the primary variables of interest, alcohol 145 
intake and adiponectin, are presented in Table 2 alongside summaries of the proportion of current 146 
smokers which also changed over time in the models estimated. The majority of the sample were non-147 
smokers and the prevalence of current smoking declined over time. Mean alcohol intake at baseline 148 
was almost 11 UK units per week, peaking at 14 units during follow-up before declining after this 149 
(consistent with previous work (13)). Mean adiponectin levels declined throughout follow-up 150 
(geometric means of 9.06, 9.05 and 9.03 at study phases 3, 5 and 7 respectively). 151 
Regression estimates 152 
Fit indices for all estimated models fell within the acceptable ranges reported above (data not shown).    153 
Presented in Table 3 are regression coefficients and standard errors from a series of linear regression 154 
models of the cross-sectional association between alcohol intake and log-transformed adiponectin 155 
levels. In both age and sex as well as fully adjusted models higher alcohol intake was associated with 156 
higher levels of circulating adiponectin (β ranging from 0.001 to 0.004 depending on phase and level 157 
of adjustment; only the phase 3 fully adjusted did not meet the threshold for statistical significance 158 
[P=0.12]). 159 
Table 4 contains regression coefficients and standard errors for two bivariate dual change score 160 
models, one with adjustment for age and sex only, and another with adjustment for ethnicity, 161 
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socioeconomic position and changes in smoking status. Alcohol intake was significantly associated 162 
with upcoming changes in itself in both models (β = -1.642 [SE 0.121] in age and sex adjusted, and β 163 
= -1.647 [SE 0.123] in the fully adjusted model). Adjustment for additional confounding factors 164 
attenuated the estimated lagged effect of adiponectin towards the null (β = 0.245 in the age and sex 165 
adjusted model compared to β = -0.047), however, in both cases the association was not statistically 166 
significant.  167 
The effect of alcohol intake on upcoming change in adiponectin was non-significant in both models (γ 168 
= -0.001 [SE 0.002] in age and sex adjusted, and γ = -0.002 [SE 0.002] in the fully adjusted model). 169 
Conclusions 170 
Summary of findings 171 
Higher alcohol intake was associated with increased levels of adiponectin when measured cross-172 
sectionally at all occasions, however, we found no evidence that alcohol consumption is associated 173 
with changes in circulating levels of adiponectin over a 10 year period in a well-documented middle 174 
age cohort of mostly white men and women. 175 
Comparison to previous work 176 
Our cross-sectional findings are broadly in agreement with existing studies on the topic of alcohol 177 
intake and adiponectin – including interventional studies (6), however, our longitudinal findings are 178 
not in line with other observational studies (12). The existing longitudinal studies have typically 179 
examined the impact of a change in alcohol consumption between two measurement occasions on 180 
adiponectin levels at a single point in time. In contrast, our primary focus was on predicting the 181 
impact of alcohol consumption on changes in adiponectin levels over time. As such our findings 182 
are not directly comparable. Whilst experimental studies have generally shown an association 183 
between alcohol intake and higher adiponectin levels it is important to note that these effects are 184 
limited to the short-term and there is substantial heterogeneity between them (6). It may therefore be 185 
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that alcohol consumption is predictive of adiponectin levels acutely but not long term, and our 186 
findings are broadly supportive of this. 187 
Adiponectin was one of several plausible biomarkers recently put forward as having compelling 188 
evidence in favour of it being a mediator in the relationship between moderate alcohol intake and 189 
reduced risk of CHD and related conditions (11). Our findings cast doubt on this assertion and add to 190 
the suspicion that a substantial proportion of the alleged protective effects of moderate alcohol intake 191 
can be explained by misclassification bias, residual confounding and failing to longitudinal dynamics 192 
between alcohol consumption and health over time (13,22,29). 193 
The role of adiponectin as an intermediate in the association between moderate alcohol intake and 194 
reduced risk of developing type 2 diabetes is further weakened when considering evidence from a 195 
large scale Mendelian randomisation study that demonstrated that adiponectin is unlikely to be 196 
causally associated with type 2 diabetes (30) (a recent meta-analysis also revealed that adiponectin 197 
levels are not predictive of coronary heart disease either (31)). 198 
Strengths and limitations 199 
Our study is the largest investigation into the role of alcohol consumption on changes in adiponectin 200 
that we are aware of, with a sample size of 2855 men and women compared to 697 men (12). Unlike 201 
other studies we were also able to use repeat measures of both alcohol intake and adiponectin. This is 202 
important as others have shown that accounting for variation in drinking over time is important when 203 
predicting health outcomes (13,32). 204 
Our study also has a number of limitations. For example, the Whitehall II study is not representative 205 
of the general population, so there may be concerns regarding the generalisability of our findings to 206 
the general population. However, it has been shown that aetiological associations observed in 207 
Whitehall II are comparable with those observed in representative samples (33). 208 
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We also concentrated on total adiponectin level but others have noted that multimetric forms of 209 
adiponectin exist (e.g. high molecular weight oligomers, trimers and hexamers) and the association 210 
between adiponectin levels and subsequent harm might be dependent on these different forms (21). 211 
Unfortunately we did not have information on this. However, this is a shared limitation with previous 212 
work looking at alcohol intake and adiponectin so should not impact comparisons made between our 213 
work and the existing evidence base.  214 
We also did not take into account beverage type, however, previous work has shown that beverage 215 
preference is not associated with the development of type 2 diabetes (34) and others have noted that 216 
often beverage specific effects are likely to be confounded by socioeconomic position (35–37). 217 
Finally, we only considered total weekly alcohol intake. While this does not affect comparisons 218 
between our work and existing studies that have used similar measures (12), it is nevertheless a 219 
limitation, as others have shown that drinking pattern is an important determinant of harm. We were 220 
unable to account for variation due to pattern of alcohol use per occasion (i.e. someone drinking 221 
14 UK units per day may consume 2 UK units per day over the course of a week, or 222 
alternatively reach their total intake by consuming 7 UK units on two occasions) – furthermore, it 223 
has been demonstrated that even irregular bouts of heavy drinking amongst typically moderate 224 
drinkers is associated with an increased risk of ill health (38). 225 
Conclusion 226 
We found that average weekly alcohol intake is associated with higher levels of adiponectin cross-227 
sectionally but is not associated with changes in total circulating adiponectin levels over time. Future 228 
work should examine the role of drinking pattern in the association between alcohol intake and 229 
adiponectin, as well as different forms of adiponectin. 230 
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Tables 393 
Table 1 - Basic demographic information of the sample 394 
Variable N % or Mean (Standard Deviation) 
Age 2855 49.8 (6.0) 
Sex   
Men 2107 73.8 
Women 748 26.2 
Ethnicity   
White 2650 92.8 
Non-white 205 7.2 
Socioeconomic position   
High 1193 41.8 
Intermediate 1331 46.6 
Low 331 11.6 
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Table 2 - Descriptive information for variables changing over time 395 
 Phase 3 Phase 5 Phase 7 Within-subject 
standard deviation 
 N % or Mean 
(Standard 
Deviation) 
N % or Mean 
(Standard 
Deviation) 
N % or Mean 
(Standard 
Deviation) 
 
UK units 2854 10.7 (12.6) 2795 14.3 (15.5) 2828 12.5 (13.1) 5.0 
Adiponectin† 2855 9.1 (1.1) 2855 9.1 (1.1) 2855 9.0 (1.06) 0.2 
Smoking status        
Not current 2855 88.1 2590 90.7 2636 92.3 -- 
Current 340 11.9 265 9.3 219 7.7 -- 
†Geometric mean 396 
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Table 3 - Regression coefficients (standard error) for the association between alcohol intake and 397 
adiponectin levels cross-sectionally at each study phase 398 
Differences in log(Adiponectin) Age and sex adjusted Fully adjusted 
Phase 3 Alcohol (N=2847) 0.002 (0.001)* 0.001 (0.001) 
Phase 5 Alcohol (N=2700) 0.002 (0.001)** 0.001 (0.001)** 
Phase 7 Alcohol (N=2644) 0.004 (0.001)*** 0.003 (0.001)*** 
*** p < 0.001; ** p < 0.01; * p < 0.05 399 
Fully adjusted = age, sex, ethnicity, socioeconomic position and smoking status.400 
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Table 4 - Regression coefficients (standard error) for bivariate dual change score model of alcohol intake affecting upcoming change in adiponectin 401 
levels 402 
Alcohol  ∆ Adiponectin Age and sex adjusted Fully adjusted 
Fixed effects 
  Alcohol Adiponectin Alcohol Adiponectin 
Intercept 12.757 (0.375)*** 8.950 (0.010)*** 13.839 (0.425)*** 8.972 (0.012) 
Slope (α) 25.028 (1.914)*** -2.186 (2.318) 26.953 (2.059)*** 0.444 (2.034) 
Autoproportional (β) -1.642 (0.121)*** 0.245 (0.258) -1.647  (0.123)*** -0.047 (0.226) 
Coupling (γ) -0.001 (0.002) -- -0.002 (0.002) -- 
Random effects 
Intercept/slope covariance 184.031*** -0.044 180.918*** 0.011 
Intercept covariance 0.242* 0.143 
Slope covariance 0.318 0.595 
Alcohol intercept,  
Adiponectin slope covariance 
0.160 0.287 
Adiponectin intercept, 
Alcohol slope covariance 
0.533** 0.378* 
*** p < 0.001; ** p < 0.01; * p < 0.05 403 
N=2855 404 
Fully adjusted = age, sex, ethnicity, socioeconomic position and smoking status. 405 
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Figures 406 
 407 
Figure 1 - Simplified diagram of model specification 408 
 409 
Single headed arrows indicate regression coefficients, double headed arrows indicate covariance 410 
terms 411 
